Search Results
Your search for early matches 10016 pages
Showing 3701 - 3750Neoadjuvant and Adjuvant Pembrolizumab Improves Outcomes in Early Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, analyses in the phase III KEYNOTE-522 trial have shown that the addition of pembrolizumab to neoadjuvant chemotherapy and the use of adjuvant...
Expert Point of View: Virginia Kaklamani, MD, DSc, and Minetta Liu, MD
Virginia Kaklamani, MD, DSc, Professor of Medicine and Head of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, moderated a press conference where Milan Radovich, PhD, reported the robust ability of circulating tumor DNA (ctDNA) and circulating tumor cells to predict...
Studies Show Circulating Tumor Material May Predict Outcomes After Neoadjuvant Therapy for Breast Cancer
In early triple-negative breast cancer, the presence of circulating tumor DNA (ctDNA) and circulating tumor cells after neoadjuvant chemotherapy may enable risk stratification of patients for disease recurrence and may predict outcomes, according to a preplanned correlative analysis of the phase II ...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Actively Recruiting Clinical Trials Studying Cancer Prevention Measures
This Clinical Trials Resource Guide lists actively recruiting clinical trials evaluating strategies to improve cancer prevention measures, mostly through increased rates of screening. Some of the following trials also address cancer prevention through improving knowledge of tumor biomarkers,...
Addition of Pembrolizumab to Docetaxel for Previously Treated Immunotherapy-Naive Patients With Advanced Lung Cancer
In the single-institution phase II PROLUNG trial reported in JAMA Oncology, Oscar Arrieta, MD, and Christian Rolfo, MD, PhD, and colleagues found that the addition of pembrolizumab to docetaxel improved objective response rates and progression-free survival in immunotherapy-naive patients with...
Joint Guideline Sheds Light on Management of Hereditary Breast Cancer
As germline genetic testing becomes more widespread among patients with breast cancer, recommendations for the appropriate management of patients with hereditary breast cancer are needed. Until now, no ASCO guideline has addressed the management of hereditary breast cancer, even for carriers of...
Vascular Imaging for Detection of Breast Cancer: Best of Two Worlds?
For breast imaging, contrast-enhanced mammography, which uses the anatomic imaging of a mammogram in addition to imaging neovascularity, can offer the overall screening capability of standard mammography and the sensitivity of magnetic resonance imaging (MRI) at a fraction of the cost of MRI,...
Early Signs of Activity With Immunotherapies in Low-Incidence Cancers
Immunotherapy is showing promise for patients with rare cancers, offering new treatment opportunities and clinical trials to those with previously limited options. At the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium, presenters discussed the use of immunotherapy in three low-incidence cancers: ...
Expert Point of View: Omid Hamid, MD
Omid Hamid, MD, Chief of Research/Immuno-Oncology, The Angeles Clinic & Research Institute, and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Center, Los Angeles, commented on these two studies for The ASCO Post. According to Dr. Hamid, the findings for the tumor...
New Guideline on Systemic Therapy for Melanoma Tackles Rapid Developments in Treatment Options
Systemic treatment of melanoma has changed rapidly since the introduction of ipilimumab in 2011. Newer therapies approved for melanoma since that time include immunotherapy, targeted therapy for mutation-bearing tumors, and injectional therapy for cutaneous or palpable lesions. ASCO has released...
PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer
Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...
Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab
Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed preliminary antitumor activity as a monotherapy and in combination with nivolumab in a variety of heavily pretreated patients with...
Prioritizing Patients With Metastatic Disease for Palliative Radiotherapy
In anticipation of how the COVID-19 pandemic might impact oncology care as the coronavirus spread across New York City, radiation oncologists with expertise in the management of metastatic disease and inpatient oncologic emergencies at Memorial Sloan Kettering Cancer Center (MSK) met in late winter ...
Distinct New MDS Subtype Proposed Based on Presence of Genetic Mutation
In a special report published by Malcovati et al in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) has proposed the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The...
Expert Point of View: Alexandra Leary, MD, PhD
Alexandra Leary, MD, PhD, of the Gustave Roussy Institute of Oncology, Paris, underscored the controversy surrounding the use of neoadjuvant chemotherapy in advanced ovarian cancer, suggesting the discord may be “more cultural and emotional than scientific” to some degree. “Some countries, such as ...
FDA Approves Capmatinib for Patients With Metastatic NSCLC With Confirmed MET Exon 14 Skipping
On May 6, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by...
Mortality Rate of Patients With Cancer and COVID-19 in a New York Hospital
Patients with cancer who were infected with COVID-19 were much more likely to die from the disease than those without cancer, according to research from physician-researchers at Montefiore Health System and Albert Einstein College of Medicine. Their findings were published by Mehta et al in Cancer...
FAST-Forward Trial: Long-Term Outcomes With Adjuvant Hypofractionated Radiotherapy for 1 vs 3 Weeks in Early Breast Cancer
As reported in The Lancet by Brunt et al, 5-year findings from the phase III FAST-Forward trial indicated that adjuvant radiotherapy with 26 Gy in 5 fractions over 1 week was noninferior to 40 Gy in 15 fractions over 3 weeks in preventing local tumor relapse in women with early-stage breast ...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing the risk of COVID-19...
Neoadjuvant Nivolumab for Resectable Merkel Cell Carcinoma
As reported in the Journal of Clinical Oncology by Suzanne L. Topalian, MD, and colleagues, neoadjuvant treatment with nivolumab was found to produce pathologic complete response in approximately half of patients with resectable Merkel cell carcinoma enrolled in the phase I/II CheckMate 358 trial....
ASCO Survey on Early Impact of COVID-19 on the Performance of Oncology Clinical Trials
An article by Waterhouse et al in JCO Oncology Practice presented results of a recent ASCO survey of clinical programs exploring the early impact of the COVID-19 pandemic on the performance of oncology clinical trials. Results highlighted the numerous issues faced by the programs, steps that are...
Negotiating the Obstacles to Conducting Clinical Trials of Immunotherapy During the Coronavirus Pandemic
Coronavirus disease 2019 (COVID-19) is perhaps the biggest challenge health-care systems have ever had to face. As part of a series of interviews The ASCO Post is conducting with oncologists, we talked with Charles G. Drake, MD, PhD, about the impact of COVID-19 on his practice and on the conduct...
On the Shoulders of Giants
Before the dawn of the modern antibiotic era and amid the chaos of World War II, future Professor of Radiology and Founding Dean of two American medical colleges, Dr. George T. Harrell,* penned what could now be argued was far too bold a statement. As the opening lines of his nonrandomized study...
New Research Highlights Risk of Thromboembolic Complications in Patients With COVID-19
A special report published by Oudkerk et al in the journal Radiology outlined strategies for the prevention, diagnosis, and treatment of thromboembolic complications in patients with COVID-19. Based on recent reports that demonstrated a strong association between elevated D-dimer levels and poor...
Risk-Prediction Model for Pancreatic Cancer
A risk-prediction model that combined genetic and clinical factors with circulating biomarkers may help to identify people at a significantly higher-than-normal risk of developing pancreatic cancer, according to results of a study published by Peter Kraft, PhD, and colleagues in Cancer...
AACR 2020: Cell-Free DNA Liquid Biopsy May Provide an Early Detection Test for Patients With Suspected Cancer
The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early detection test. In this phase ...
Hypercoagulability in Critically Ill Patients With COVID-19: Where Do We Stand?
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” ―Hippocrates The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Connors...
AACR 2020: ctDNA May Be a Prognostic Biomarker of Disease Recurrence in Patients With Lung Cancer
The TRACERx study investigated phylogenetic tracking and minimal residual disease (MRD) detection using circulating tumor DNA (ctDNA) profiling following resection in patients with stage I to III non–small cell lung cancer (NSCLC). Investigators found that ctDNA is an adjuvant biomarker capable of...
Adapting Adjuvant Endocrine Therapy by Patient Age and Risk
The individualization and optimization of adjuvant endocrine therapy for breast cancer are important and not always simple. Guidance on this issue was offered at the 2020 Miami Breast Cancer Conference by Joyce O’Shaughnessy, MD, the Celebrating Woman Chair in Breast Cancer Research at Baylor...
21-Gene Assay Recurrence Score and Risk of Locoregional Recurrence in Hormone Receptor–Positive, Node-Positive Breast Cancer
A retrospective analysis from the Southwest Oncology Group S8814 trial, reported by Wendy A. Woodward, MD, PhD, of the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and colleagues in JAMA Oncology,1 showed that a low 21-gene assay recurrence score was...
Radon Exposure: A Leading Environmental Cause of Cancer Mortality in the United States
The Environmental Protection Agency (EPA) has concluded that about 21,000 people die each year of lung cancer related to radon gas exposure, making it the second leading cause of lung cancer death in the United States. Although the EPA and various other organizations, including the National Radon ...
PD-1 Inhibition in Mismatch Repair–Deficient/Microsatellite Instability–High Cancers Other Than Colorectal Cancer
Mismatch repair (MMR)-deficiency and consequently high DNA microsatellite instability (MSI-H) are associated with high tumor mutational burden. A high mutational load increases the potential number of neoantigens that can be presented by the tumor cell and recognized by host lymphocytes. Detection...
Selected ASH Abstracts on Novel Treatments for Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...
How CRISPR-Cas9 Gene Editing May Improve the Effectiveness of Cellular Therapeutics in Patients With Cancer
The results from the first in-human phase I clinical trial in the United States evaluating CRISPR-Cas9–edited T cells in patients with advanced cancer has shown that the therapy is both feasible and safe, representing a big step forward in the potential of using gene editing to boost the natural...
ASCENT Study Halted: Efficacy Shown Across Multiple Study Endpoints in Triple-Negative Breast Cancer
The phase III confirmatory ASCENT study of the antibody drug-conjugate sacituzumab govitecan will be stopped based on efficacy across multiple study endpoints following unanimous recommendation from the independent data safety monitoring committee, according to a news release issued earlier this...
Beyond CDK4/6 Inhibitors: What Subsequent Treatment Is Best?
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have changed the natural history of hormone receptor–positive metastatic breast cancer. While median progression-free survival on these drugs is approximately 27 months, the disease eventually progresses and clinicians must choose a subsequent ...
More Antibody-Drug Conjugates on the Horizon for Breast Cancer
Novel antibody-drug conjugates that target actionable cell-surface markers in metastatic breast cancer will soon expand the utility of the class that already includes ado-trastuzumab emtansine (T-DM1), according to two speakers at the 2020 Miami Breast Cancer Conference. These new agents were...
Do HIV Positivity and Autoimmune Disease Preclude Treatment With Checkpoint Inhibitors?
Can patients with cancer and preexisting autoimmune disorders safely benefit from immunotherapy? The answer has been unclear, with only retrospective studies and anecdotal reports guiding oncologists. This subpopulation of patients has largely been excluded from clinical trials out of concerns over ...
What’s the Current Status of Neoadjuvant Immunotherapy?
For several tumor types, can the successes achieved with immunotherapy in the metastatic and adjuvant settings be replicated in the neoadjuvant setting? An explosion in clinical trials—with more than 300 listed on ClinicalTrials.gov—point to “yes.” “The neoadjuvant use of immunotherapy is of great ...
Upfront Apalutamide Delays Time to Second Progression in Metastatic Castration-Sensitive Prostate Cancer
The addition of apalutamide to androgen-deprivation therapy (ADT) reduced the risk of second disease progression or death (PFS2) by 34% vs ADT alone in patients with metastatic castration-sensitive prostate cancer, in a post hoc analysis of the phase III TITAN trial presented at the 2020...
Merry-Jennifer Markham, MD, FACP, FASCO, Rose From Humble Beginnings to a Leadership Role in Oncology
Merry-Jennifer Markham, MD, FACP, FASCO, grew up in Fort White, Florida, a rural speck on the map in the northern part of the state. Fort White is home to the Ichetucknee River and Springs, a crystal-clear natural wonder known only to the locals until 1972, when it was declared a National Natural...
Conquer Cancer Researchers Remember Jane C. Wright, MD, FASCO
It’s 1964 in Chicago. Seven forward-thinking oncologists gather to brainstorm what will become the American Society of Clinical Oncology (ASCO). Among the group is Jane C. Wright, MD, FASCO, the only woman and African American among ASCO’s founders. It’s time for the 2011 ASCO Annual Meeting in...
FDA’s Draft Guidance Will Improve Evidence Base for Older Adults With Cancer
ASCO commends the U.S. Food and Drug Administration (FDA) for releasing draft guidance that encourages inclusion of older adults in clinical trials of drugs for the treatment of cancer. The guidance emphasizes the importance of including adults aged 75 or older in clinical trials to better enable...
Pembrolizumab Plus Cetuximab Shows Antitumor Activity in Squamous Cell Head and Neck Cancer
The first trial to evaluate anti–programmed cell death protein 1 (PD-1) blockade combined with epidermal growth factor receptor (EGFR) inhibition in head and neck squamous cell carcinoma demonstrates promising activity of the drug combination in patients with platinum-refractory or -ineligible...
It’s T Time for Peripheral T-Cell Lymphoma, a Much-Neglected Disease
The lymphomas are an incredibly complex assemblage of neoplastic diseases. They are not one disease, and, at least based on the World Health Organization (WHO) Classification of Tumors published in 2017, they represent a collection of approximately 80 different malignancies, a number that will...
Inoperable Carcinoma of the Breast
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The X-Ray Era: 1901–1915 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Dr. Burns and The Burns Archive. To view ...
Chemotherapy and the Sweat Lodge
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Gut Microbiota Emerging as Key Player in Response to Immunotherapy
The microbiome—and the foods that feed it—is emerging as an important determinant of a patient’s response to immunotherapy. Much of the research in this area comes from The University of Texas MD Anderson Cancer Center, as described at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium by...
After Training Across Three Continents, a Hematologist Leads the Wisconsin Hematology/Oncology Division
In this edition of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with hematologist Parameswaran Hari, MD, MRCP, Chief of the Division of Hematology and Oncology at the Medical College of Wisconsin, Milwaukee. In addition, Dr. Hari holds the Armand J. Quick/William F. Stapp Chair...
